ArrowHead Pharma

Forecast & Rating16 analysts currently cover ArrowHead Pharma, with about 87.5% giving a positive rating — meaning they expect the stock to rise. The average price target is $107.71, about 83.1% upside from the current price of $58.84. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 25.7% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study ArrowHead Pharma closely still see room for the stock to rise. Data as of Oct 21, 2026; for reference only and not investment advice.